Equities Analysts Issue Forecasts for STOK FY2029 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at HC Wainwright cut their FY2029 earnings estimates for shares of Stoke Therapeutics in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of $1.51 per share for the year, down from their previous estimate of $1.55. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2030 earnings at $3.48 EPS.

STOK has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Wedbush raised their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Guggenheim reissued a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Canaccord Genuity Group dropped their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They set an “overweight” rating and a $40.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.17.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $26.48 on Tuesday. The stock’s 50 day moving average price is $27.31 and its 200 day moving average price is $30.87. Stoke Therapeutics has a 1-year low of $20.32 and a 1-year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.15). The business had revenue of $11.26 million for the quarter, compared to analyst estimates of $8.21 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.

Institutional Trading of Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Alps Advisors Inc. grew its stake in shares of Stoke Therapeutics by 35.7% during the 3rd quarter. Alps Advisors Inc. now owns 85,483 shares of the company’s stock valued at $2,223,000 after buying an additional 22,473 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Stoke Therapeutics in the 3rd quarter worth $86,000. China Universal Asset Management Co. Ltd. raised its position in shares of Stoke Therapeutics by 29.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,054 shares of the company’s stock worth $338,000 after buying an additional 2,942 shares during the period. SYM FINANCIAL Corp acquired a new position in Stoke Therapeutics in the third quarter valued at $1,562,000. Finally, Sterling Capital Management LLC boosted its holdings in Stoke Therapeutics by 849.7% in the third quarter. Sterling Capital Management LLC now owns 1,833 shares of the company’s stock valued at $48,000 after acquiring an additional 1,640 shares during the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 5,545 shares of Stoke Therapeutics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total transaction of $170,065.15. Following the completion of the transaction, the insider owned 20,110 shares in the company, valued at approximately $616,773.70. The trade was a 21.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the sale, the general counsel directly owned 21,225 shares in the company, valued at $679,836.75. This trade represents a 11.88% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 27,418 shares of company stock worth $860,914. 9.60% of the stock is owned by corporate insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.